About Us

Why work with Nauka?

Deep Scientific Expertise

Strategic Thinking

Experience: > 1000 BD opportunities evaluated

Knowledge of Pharma: Drug Development, Pipeline Strategy and Dealmaking

Industry connections: Drug Developers, BD professionals, VCs, Investment bankers

About Us

Our Services

Consulting Services We Offer

We are experts in corporate development and strategic partnering

Due Diligence for BD transactions

Product differentiation, data gaps. Pharma perspectives.

Product/ Portfolio Strategy and Corporate Development

Product-Market Fit, KOL engagement, New Product Planning

Market Research and Commercial Assessments

Market sizing validation, secondary and primary market research, competitive landscaping, financial modeling/ valuation.

Business Development Support

Strategic Partnering Roadmap, Pitch Deck improvement, BD outreach, negotiations and execution of deals

Collaborate With Our Expert Consultant Today

Natalia Ulyanova is an experienced BD/ Corporate Development professional with 10+ years of experience in academic cancer research, 6+ years in Pharma BD & Licensing, Search and Evalution, and Transactions, 4+ years in Strategic Life Sciences Consulting and 2+ years in biotech BD and operations.

Read More

15 Consulting

Projects

5 Clinical stage therapeutics

+6 medical device/ Dx

17 Strategic BD Deals

Over $8.5B Total Value

FAQ

Frequently Asked Questions

What does Nauka stand for?

Nauka means ‘Science’ in Russian and many Slavic languages. The word has origins in Sanskrit’s ‘Nau’ = ship, and symbolizes knowledge, wisdom and exploration

Is this Natalia Ulyanova in the pic?

Yes, at a panel presentation at LSX World Congress, Sep 2024. Natalia presented on the topic of Oncology Partnering as an invited Speaker over a dozen times in recent years, e.g., at the Pharma Partnering Summit, CAR-TCR Summit, ADC and Radiopharma Partnering, Next Gen Ungruggable, Oncolytic Virotherapy, AUTM Oncology, etc.

I have a great molecule, why is Pharma not interested? Can you help change that?

Drug development is expensive and risky, therefore, Pharma is very selective. Your molecule has to fit with the pharma partner’s strategic focus and all the other magic stars also have to align for the deal to happen. We can help improve the chances by crafting an appealing story and communication plan and applying our BD expertise from planning to execution

Are you a sell-side or a buy-side BD professional?

We are focused on strategic partnering – R&D collaborations, in- and out-licensing and we have executed deals from both sides successfully.

What kind of Due Diligence support do you offer?

We can support technical/scientific evaluation, organize cross-functional due diligence process and integrate expert insights from clinical, CMC, regulatory, legal/IP, financial, CMC, etc. into actionable recommendations

News & Articles

Latest News And Articles